Trexquant Investment LP Raises Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Trexquant Investment LP lifted its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 97.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,954 shares of the biotechnology company's stock after purchasing an additional 67,040 shares during the period. Trexquant Investment LP owned 0.64% of Enanta Pharmaceuticals worth $782,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. AlphaQuest LLC boosted its stake in Enanta Pharmaceuticals by 16.4% during the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock worth $128,000 after buying an additional 3,137 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Enanta Pharmaceuticals by 10.5% during the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company's stock valued at $213,000 after acquiring an additional 3,501 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $26,000. FMR LLC grew its holdings in shares of Enanta Pharmaceuticals by 18.9% in the third quarter. FMR LLC now owns 49,301 shares of the biotechnology company's stock valued at $511,000 after purchasing an additional 7,839 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $58,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. JMP Securities reiterated a "market outperform" rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. StockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th. Finally, HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.25.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA traded up $0.12 during mid-day trading on Thursday, reaching $5.05. 77,963 shares of the company were exchanged, compared to its average volume of 283,680. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.09 and a 1 year high of $17.24. The firm's 50-day simple moving average is $6.31 and its 200 day simple moving average is $7.58. The firm has a market cap of $107.73 million, a price-to-earnings ratio of -1.02 and a beta of 0.69.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly bought 45,000 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The shares were purchased at an average cost of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares in the company, valued at approximately $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.89% of the stock is currently owned by company insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.